Announcement PDF ASX Announcement 26 February 2026 JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 Appendix 4D & FY26 Interim Report Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company driven to improve human health, is pleased to announce its results for the six-month period ended 31 December 2025 (“H1 FY26”). Key Highlights Testing Core test volume and market development • 10,258 core tests sold globally in H1 FY26, up 113% vs PCP • Annualised run rate surpassed 21,300 tests, on track for 24,000+ for FY26 • Microbiome Explorer increased from 20% to 55% of total revenue vs PCP • Completed strategic discontinuation of all legacy products Australia - Continued record growth for Microbiome Explorer • 8,244 tests sold in H1 FY26, up 87% vs PCP • 878 ordering clinician accounts, up 19% vs PCP • H1 growth underpinned by increases in both ordering clinicians and orders per clinician • Adoption advancing into early adopter segment with 12 enterprise clinic contracts signed since November 2025 Australia - MetaPanel steady clinical adoption • 503 tests sold in H1 FY26, up 20% vs PCP • Clinical adoption continuing to build in partnership with Sonic Healthcare (ASX: SHL) • Focus on organic development of Gastroenterology specialists to drive broader clinician market adoption United Kingdom - Microbiome Explorer strong market development • 1,511 Microbiome Explorer tests sold in H1 FY26, first full half of UK market access • UK adoption outperforming Australia by 33% at an equivalent time post launch • All legacy UK testing products discontinued; Microbiome Explorer represents 100% of GI tests sold • Supplements business remains robust, with Invivo branded products achieving a record quarter Therapeutics Partnering phase advancement • Transitioned to active partnering phase; no further R&D expenditure • Multiple positive sector readouts validating the live biotherapeutic modality • Active in partnering discussions with deal precedents of $1.5B to $11B ASX Announcement 26 February 2026 JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 Additional Achievements • Completed major Microba brand update, consolidating global brands and driving operational and marketing efficiency • AI implementation delivering measurable efficiency gains across customer support, engineering, and scientific operations • Five key product features released during the half, supporting high-volume clinician adoption and enterprise accounts • Global laboratory consolidation completed, expected to deliver over $1.0m in cost savings over 24 months • Board renewal with appointment of Mr Stéphane Chatonsky as Independent Non-Executive Director Financial Metrics • H1 FY26 revenue of $7.32 million, down 9% vs PCP, aligned to legacy product discontinuation, core testing revenue up 123% • H1 FY26 Growth product revenue of $4.0 million, up 135% vs PCP • Staff costs reduced $2.0m annually through global efficiencies and restructuring initiatives • $11.27 million in cash and equivalents at 31 December 2025 • On track for regional break-even by end of FY26 Commenting on the Interim Report, Microba CEO Dr Luke Reid said: “The first half of FY26 delivered strong continued growth of our core testing products, reaching an annualised run rate of over 21,300 tests and tracking towards our regional break-even guidance. We sold over 10,000 core tests in the half, more than doubling the prior corresponding period.” “Q2 marked the completion of our strategic transition, finalising the discontinuation of all legacy product sales. From Q3 we will present a clean revenue growth picture with no remaining legacy product impact, and we are confident in accelerating top-line momentum.” “We completed a major brand and operational consolidation during the half, unifying our global brands, rebuilding our marketing engine, and consolidating our global laboratory footprint. We are already seeing tangible results - reducing clinician signup to first referral from over 12 days to under 2 days, and the laboratory consolidation alone is expected to deliver more than $1 million in cost savings over 24 months. Combined with our restructuring initiatives, which have reduced underlying staff costs by $2 million annually, we are building significant operating leverage into the business as we scale. In the UK, adoption is outperforming Australia by 33% at equivalent time post launch, and in Australia we are now signing enterprise-style clinic contracts as we move into the early adopter segment.” “For our therapeutic assets, multiple positive sector readouts are validating the live biotherapeutic modality, creating an environment for deal activity. We remain intensively focused on executing our commercial growth strategy, advancing towards regional break-even in FY26, and capturing the significant opportunity ahead in this major new diagnostic category.” View this announcement on Microba’s Investor Hub: https://ir.microba.com/link/yVQV5P ASX Announcement 26 February 2026 JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 This announcement has been authorised for release by the Board of Directors. For further information, please contact: Dr Luke Reid Chief Executive Officer luke.reid@microba.com Investor / Media Relations investor@microba.com https://ir.microba.com/welcome About Microba Life Sciences Limited Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com Microba Life Sciences Limited and controlled entities Appendix 4D Half-year report 1. Company details Name of entity: Microba Life Sciences Limited ABN: 82 617 096 652 Reporting period: For the half-year ended 31 December 2025 Previous period: For the half-year ended 31 December 2024 2. Results for announcement to the market $ Revenues from ordinary activities down 9.5% to 7,319,904 Loss from ordinary activities after tax attributable to the owners of Microba Life Sciences Limited up 83.9% to (10,556,230) Loss for the half-year attributable to the owners of Microba Life Sciences Limited up 83.9% to (10,556,230) Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the Group after providing for income tax amounted to $10,556,230 (31 December 2024: $5,741,685). 3. Net tangible assets Reporting period Previous period Cents Cents Net tangible assets per ordinary security 1.09 1.57 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividends Current period There were no dividends paid, recommended or declared during the current financial period. Previous period There were no dividends paid, recommended or declared during the previous financial period. 7. Dividend reinvestment plans Not applicable. 1 FY26 INTERIM REPORT Microba Life Sciences Limited and controlled entities Appendix 4D Half-year report 8. Details of associates and joint venture entities Not applicable. 9. Foreign entities Details of origin of accounting standards used in compiling the report: Not applicable. 10. Audit qualification or review Details of audit/review dispute or qualification (if any): The financial statements were subject to a review by the auditors and the review report is attached as part of the Financial Report. 11. Attachments Details of attachments (if any): The Financial Report of Microba Life Sciences Limited for the half-year ended 31 December 2025 is attached. 12. Signed Signed ___________________________ Date: 26 February 2026 Pasquale Rombola Director Brisbane Authorised for release by the Board. 2 FY26 INTERIM REPORT Interim Financial Report For the six months ended 31 December 2025 Microba Life Sciences Limited ABN 82 617 096 652 Microba Life Sciences Limited and controlled entities Performance Highlights Therapeutics Partnering phase advancement • Transitioned to active partnering phase; no further R&D expenditure • Multiple positive sector readouts validating the live biotherapeutic modality • Active in partnering discussions with deal precedents of $1.5B to $11B Additional Achievements • Completed major Microba brand update, consolidating global brands and driving operational and marketing efficiency • AI implementation delivering measurable efficiency gains across customer support, engineering, and scientific operations • Five key product features released during the half, supporting high-volume clinician adoption and enterprise accounts • Global laboratory consolidation completed, expected to deliver over $1.0m in cost savings over 24 months • Board renewal with appointment of Mr Stéphane Chatonsky as Independent Non-Executive Director Financial Metrics • H1 FY26 revenue of $7.32 million, down 9% vs PCP, aligned to legacy product discontinuation (core testing revenue up 123%) • H1 FY26 Growth product revenue of $4.0 million, up 135% vs PCP • Staff costs reduced $2.0m annually through global efficiencies and restructuring initiatives • $11.27 million in cash and equivalents at 31 December 2025 • On track for regional break-even by end of FY26 Testing Core test volume and market development • 10,258 core tests sold globally in H1 FY26, up 113% vs PCP • Annualised run rate surpassed 21,300 tests, on track for 24,000+ for FY26 • Microbiome Explorer increased from 20% to 55% of total revenue vs PCP • Completed strategic discontinuation of all legacy products Australia - Continued record growth for Microbiome Explorer™ • 8,244 tests sold in H1 FY26, up 87% vs PCP • 878 ordering clinician accounts, up 19% vs PCP • H1 growth underpinned by increases in both ordering clinicians and orders per clinician • Adoption advancing into early adopter segment with 12 enterprise clinic contracts signed since November 2025 Australia - MetaPanel™ steady clinical adoption • 503 tests sold in H1 FY26, up 20% vs PCP • Clinical adoption continuing to build in partnership with Sonic Healthcare (ASX: SHL) • Focus on organic development of Gastroenterology specialists to drive broader clinician market adoption United Kingdom - Microbiome Explorer strong market development • 1,511 Microbiome Explorer tests sold in H1 FY26, first full half of UK market access • UK adoption outperforming AU by 33% at equivalent time post launch • All legacy UK testing products discontinued; Microbiome Explorer represents 100% of GI tests sold • Supplements business remains robust with Invivo branded products achieving a record quarter FY26 INTERIM REPORT 4 Directors Key management personnel Company Secretary Registered office and principal place of business Share register Auditor Solicitors Stock exchange listing Website Corporate Governance Statement Corporate Directory Pasquale Rombola Ian Frazer Gene Tyson Jacqueline Fernley Stéphane Chatonsky Luke Reid (Chief Executive Officer) James Heath (Chief Financial Officer) James Heath Microba Life Sciences Limited Level 10 324 Queen Street Brisbane QLD Australia Automic Pty Ltd Level 35 477 Collins Street Melbourne VIC Australia Pitcher Partners Level 38 345 Queen Street Brisbane QLD Australia Thomson Geer Level 28 1 Eagle Street Brisbane QLD Australia Microba Life Sciences Limited shares are listed on the Australian Securities Exchange (ASX code: MAP) www.microba.com The Company’s corporate governance statement is located at the Company’s website: https://ir.microba.com/corporate-governance FY26 INTERIM REPORT 5 Review of Operations 01 FY26 INTERIM REPORT 6 Review of Operations The Directors of Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) are pleased to present their Review of Operations for the half-year ended 31 December 2025 (“H1 FY26”) in conjunction with the financial statements of Microba Life Sciences Limited and its subsidiaries (together referred to as the “Group”), and the auditor’s report thereon. The financial statements have been reviewed by the Company’s auditor and approved by the Directors. Microba is creating a new diagnostic category in clinical microbiome testing, which the Company estimates represents a market opportunity exceeding US$100 billion. Over recent years, Microba has strategically invested to unlock the human gut microbiome, leveraging its world-leading technology to pioneer the development of clinical microbiome diagnostics and novel biotherapeutics. This investment is now yielding accelerating results, with the first half of FY26 delivering the strongest period of core test growth in the Company’s history. The Company’s core testing products - Microbiome Explorer (formerly MetaXplore) and MetaPanel - achieved combined sales of 10,258 tests in H1 FY26, more than doubling the prior corresponding period. The annualised run rate surpassed 21,300 tests, tracking towards the Company’s FY26 guidance of 24,000+ core tests, aligned to regional break-even objectives for both Australia and the United Kingdom. H1 FY26 revenue was $7.32 million, down 9% on the prior corresponding period, reflecting the planned roll-off of discontinued legacy product revenue. Core testing revenue grew 123% versus PCP, with Growth product revenue reaching $4.0 million, up 135% versus PCP. The statutory loss before income tax increased compared with the prior corresponding period, primarily reflecting several material one-off and non-cash items associated with legacy product discontinuation, portfolio transition activities and foreign exchange movements; excluding these items, the net loss decreased when compared with H1 FY25. As at 31 December 2025, Microba held $11.27 million in cash and cash equivalents. H1 FY26 represented a transformational period of strategic transition. The Company completed the discontinuation of all legacy testing products and services, enabling 100% focus on its core Growth testing products. Microbiome Explorer now represents 55% of total revenue, up from 20% in the prior corresponding period. From Q3 FY26, the Company’s revenue will reflect a clean growth profile with no further legacy product roll-off. FY26 INTERIM REPORT 7 Review of Operations Testing Business Advancement Australia - Microbiome Explorer™ Gastrointestinal Disorder Test The Microbiome Explorer test (formerly MetaXplore) provides the most comprehensive gastrointestinal testing solution available to healthcare professionals, combining diagnostic gastrointestinal health tests with metagenomic-driven gut microbiome analysis. The Microbiome Explorer test range, developed by Microba together with leading healthcare professionals, addresses a large market of patients suffering from functional gastrointestinal disorders which impact more than 30% of the population. Microba continued to see record growth in Microbiome Explorer test sales in Australia throughout H1 FY26: Growth in H1 FY26 was underpinned by increases in both the number of ordering clinicians and the volume of orders per clinician. Strategic clinician education, targeted field sales execution, ongoing product feature releases, and digital-led product-assisted growth systems delivered consistent growth momentum across both quarters of the half, with Q2 FY26 achieving a new record despite the traditional seasonal softness of the December holiday period. Notably, adoption has now advanced beyond innovator clinicians into the early adopter segment of the customer adoption curve. This shift is increasingly characterised by enterprise- style contracts with small to medium healthcare groups. Since November 2025, Microba has signed 12 clinic account contracts in Australia, representing meaningful recurring volume potential. This progression supports accelerating revenue growth while improving sales efficiency through higher average revenue per account. Category creation requires disciplined execution aligned to the customer adoption curve. Microba’s strategy is designed to de-risk this process through a structured, region-by-region market development process. In Australia, clinical testing commenced in April 2023 with innovator clinicians and has now successfully progressed through to early adopter uptake, supported by continuous product advancement, clinical evidence generation, and expanding key opinion leader advocacy. H1 FY26 H1 FY25 (PCP) Change Tests Sold 8,244 4,400 Up 87% Ordering Clinicians (at period end) 878 735 Up 19% FY26 INTERIM REPORT 8 Review of Operations Australia - MetaPanel™ Gastrointestinal Pathogen Test In H1 FY26, the Company made steady progress in driving MetaPanel adoption with general practitioners and gastroenterologists across Australia together with its partner Sonic Healthcare (ASX: SHL). MetaPanel is a world-first NATA accredited test for diagnosing gastrointestinal pathogens. It is the most comprehensive gastrointestinal pathogen test available, detecting both common and difficult-to-identify pathogens capable of causing infection. The Company remains in an early market development phase for MetaPanel, with a focus on organic development of Gastroenterology specialist adoption. KOL engagement, evidence generation activities and utility publications are continuing to support clinician adoption in collaboration with Sonic Healthcare. A gradual rate of adoption is expected over the next year, with FY27 presenting the opportunity for larger volume growth as the consistent KOL and evidence development work translates into broader adoption and routine referral behaviour. United Kingdom - Microbiome Explorer A fundamental investment thesis of the Invivo Healthcare acquisition was the ability to accelerate Microba’s entry of its world-leading Microbiome Explorer test into the United Kingdom through an established team and customer base. H1 FY26 captured the first full half-year of market access for Microbiome Explorer in the UK, following the completion of early access programs and full market launch in Q4 FY25. * UK full market access commenced Q4 FY25; no comparable PCP for the full half. UK adoption is outperforming Australia by 33% at the equivalent time post launch, reflecting the strategic rationale of the Invivo Healthcare acquisition in leveraging an established customer base for a running start. The quarterly trend between Q1 and Q2 mirrors the seasonal pattern observed at the equivalent post-launch period in Australia, with both markets H1 FY26 H1 FY25 (PCP) Change Microbiome Explorer Tests Sold 1,511 N/A* N/A Ordering Clinicians (Q2 end) 268 N/A* N/A H1 FY26 H1 FY25 (PCP) Change Tests Sold 503 420 Up 20% FY26 INTERIM REPORT 9 Review of Operations experiencing the same holiday period impact. This provides confidence in the underlying adoption trajectory. The strategic transition to Microbiome Explorer as the sole UK testing product is now complete, with all legacy EcologiX products discontinued. MetaXplore (now Microbiome Explorer) represents 100% of gastrointestinal tests sold in the United Kingdom. The UK adoption is expected to continue to accelerate across 2026, leveraging the historical Invivo customer base, product advancement and feature releases, and global marketing efficiency. United Kingdom - Nutritional Supplements The UK supplements business commenced it’s strategic transition towards higher-margin Invivo branded and owned products, moving away from third-party distributed Designs For Health (DFH) branded products. Invivo branded supplements delivered a record quarter in Q2 FY26, supported by breakout results from the PHGG prebiotic fibre supplement (volume up 110% vs PCP). Execution on Amazon advanced sales ranking from 99th to 12th position in the fibre category in the UK since September. A subscription offering was launched in October and has grown to over 300 subscribers. Growth has been driven by targeted digital campaigns, distributor account management, and the commencement of influencer and affiliate marketing campaigns. H1 FY26 H1 FY25 (PCP) Change Invivo Supplements Revenue $1.38m $1.23m Up 12% Distributed Supplements (DFH) $0.70m $1.37m Down 49% The Invivo Healthcare nutritional supplement business was placed under the leadership of a dedicated CEO with a high-performance team in Q2 FY26. The team are focused on the USD 7 billion fibre supplement subcategory of the gut health supplement market. There is a profound and global gap between dietary fibre recommendations and actual consumption. Over 90% of adults fail to meet the recommended intake - this gap represents both a major public health challenge and a significant commercial opportunity. FY26 INTERIM REPORT 10 Review of Operations Brand Consolidation and Operational Efficiency The entire marketing engine and customer-facing surfaces were rebuilt under the new brand, enabling streamlined global lifecycle marketing. An early and significant result has been the delivery of a new practitioner onboarding welcome sequence that reduced clinician signup- to-first-referral time from 12.4 days in November to 1.7 days in January - a transformative improvement in activation speed. As part of the brand update, product names were refreshed for simplicity and clarity. MetaXplore is now known as Microbiome Explorer™, available in three variants: Comprehensive (available in Australia and the UK), Essentials (available in Australia, coming to the UK in Q3), and Extended (available in Australia, coming to the UK in Q3). AI Implementation AI implementation across all business functions is delivering measurable efficiencies, improved customer experiences, and operational advancements that position the Company for long- term success. Key AI achievements in H1 FY26 include: deployment of an AI-powered customer support agent that has successfully resolved 71.4% of inquiries autonomously with a 94.7% customer satisfaction score; AI-assisted software engineering increasing developer productivity by 1.5x and expected to reach 3x during the year; and AI-driven scientific literature review and grading reducing required human hours by 30%, with a target to surpass 50%. These are examples within a comprehensive AI rollout spanning all aspects of the business, including advanced analytics for data-driven decision making, intelligent operational automation, and innovative applications in product development and marketing. Product Feature Releases Multiple product features were released during H1 FY26, aligned to the needs of target healthcare professionals and clinics as the Company progresses through the customer adoption curve: In November 2025, Microba completed a major brand update that consolidated its global testing brands - Microba, Co- Biome, Invivo, MetaXplore and MetaPanel - under a single Microba brand. This was not a cosmetic refresh; it was a strategic initiative to drive operational efficiency and increased marketing effectiveness at scale. FY26 INTERIM REPORT 11 These features have directly driven conversion of high-volume target healthcare professionals and clinics, supporting the Company’s advancement along the adoption curve from innovators to early adopters. Global Laboratory Consolidation During Q2 FY26, the Company completed the consolidation of its global laboratory footprint. This initiative is expected to deliver more than $1.0 million in cost savings over the next 24 months, while also improving cost of goods sold through greater testing volume concentration and economies of scale. Therapeutic Business Advancement All further investment in research and development has been ceased at this time. Microba maintains its competitive advantage in human data-driven discovery from the human microbiome and holds field-leading live biotherapeutic IP assets with deep preclinical and early clinical validation, including MAP315 which is near Phase 2 ready. Sunday Collection and Simplified Instructions - Expanding the sampling window, reducing friction, improving patient convenience, and reducing component costs by approximately 18% Review of Operations Practitioner Pays - A new payment workflow enabling clinicians to order and pay for tests directly on behalf of patients, streamlining the ordering process and increasing conversion Admin Accounts - Allows designated support staff to manage patient records, referrals and reports on behalf of practitioners, reducing administrative burden in busy multi-practitioner clinics Oral Species Biomarker - A new biomarker detecting the presence of over 410 oral-origin species in the gut, identifying hidden contributors to intestinal inflammation and impacts of PPI use Pay on Invoice - Supporting enterprise sales workflows with 30-day payment terms for high-volume clinics and practitioners FY26 INTERIM REPORT 12 Review of Operations The Company has transitioned from an R&D investment phase to an active partnering phase, with the team focused on securing partnerships and transactions that realise the value of these assets. Deal precedents in the live biotherapeutic sector range from $1.5 billion to $11 billion. Sector Clinical Trial Readouts Validating the Modality The live biotherapeutic modality has been maturing in its development, with many prospective partners awaiting definitive Phase 1b/2a efficacy data in chronic disease indications to validate this new therapeutic class. Aligned to this, the Company has guided on clinical trial readouts from peer companies that would provide that validation. Multiple positive readouts have now been delivered: These positive sector readouts have begun to change the temperature of partnering discussions. The Company is very active in its partnering work leveraging this validating sector momentum. A transaction on therapeutic assets, particularly MAP-315, would be expected to have a material impact on the valuation of Microba and set the foundation for realising the true value of its therapeutic platform. Siolta Therapeutics - Phase 1b in paediatric allergic disease: Positive (November 2025). A significant result for the sector, demonstrating efficacy of live biotherapeutics in allergic disease Microbiotica - Phase 1b in mild-to-moderate Ulcerative Colitis: Positive (11 February 2026). Met primary endpoints, providing further validation of the live biotherapeutic modality in a major chronic disease setting MaaT Pharma - Phase 3 in gastrointestinal acute Graft-versus-Host Disease: Positive final pivotal results (December 2025). Now under regulatory review by the European Medicines Agency for Market Approval, with a decision expected mid-2026. This stands to be the first market approval for a microbiome therapeutic in a chronic, non- infection setting Enterobiotix - Phase 2a in Irritable Bowel Syndrome: Positive (January 2026). Met primary endpoints, further validating the modality FY26 INTERIM REPORT 13 Review of Operations Financial Overview H1 FY26 revenue totalled $7.32 million, a decrease of 9% versus the prior corresponding period. The revenue reduction predominantly reflects the planned roll-off of discontinued legacy product revenue which were completed during Q2 FY26. Excluding these exited revenue streams, underlying performance was driven by strong growth in core testing products, with core testing revenue increasing 123% versus PCP. Growth product revenue for the half reached $4.0 million, up 135% versus PCP, while legacy product revenue declined to $0.7 million as the final discontinued products and services wound down. The statutory accounting loss for H1 FY26 was $10.56 million, compared to $5.74 million in the prior corresponding period, an increase of 83.9%. The year on year movement includes several material, non-recurring and non-cash line items, these predominantly relate to the completion of strategic discontinuation of all legacy products during the half, including $1.7m variance in foreign exchange and fair value movements largely relating to intercompany loan revaluation at period end, a $0.75m non-cash write-off associated with discontinued legacy testing technology, $0.66m relating in restructuring expense, and the absence of $2.45m of other income recognised in H1 FY25 relating to unwinding of the Invivo contingent consideration. After adjusting for non-cash and non-recurring items in both periods, including the prior year $2.45 million contingent consideration credit, foreign exchange revaluation movements, impairment of discontinued legacy technology, restructuring costs and tax adjustments, the underlying loss for H1 FY26 was $8.73 million compared to $9.27 million in H1 FY25, representing a 5.8% improvement on underlying loss on a like-for-like basis. Operating cash outflows for the half were $5.7 million, further highlighting the distinction between the statutory accounting loss and underlying cash performance. During the period, the Company completed the transfer and wind-down of non-core revenue streams and implemented structural cost reductions, lowering the ongoing operating cost base entering the second half of FY26. In Q2 alone, more than $1.6 million of discontinued legacy product revenue was replaced by growth product revenue. From Q3 FY26, reported revenue performance will no lon